Login
$RPRX
$68.19 -$0.34 (0.49%) After hours

Insider Transactions

What Royalty Pharma plc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

3 months 12 months
Open-market buys 0 0
Sells 5 72
Total trades 14 104

Shares traded

3 months 12 months
Acquired 0 0
Disposed 0 0
Net activity +0 +0

Common stock only — 104 reported trades in the last 12 months are in a security these totals do not cover.

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

Insider Relation Date Transaction Shares Price Value Shares held
Coyne Terrance P. EVP & CFO Nov 06 Derivative Conversion · C RPRX +100,000 — — 100,000
Coyne Terrance P. EVP & CFO Nov 06 Derivative Conversion · C RPRX +150,000 — — 150,000
Urist Marshall EVP, Research & Investments Nov 06 Derivative Conversion · C RPRX +150,000 — — 150,000
Coyne Terrance P. EVP & CFO Nov 04 Grant / award · A RPRX +7,122 — — 7,122
Hite Christopher EVP & Chairman, Partnering Nov 04 Grant / award · A RPRX +7,122 — — 277,523
Legorreta Pablo G. CEO, Chairman of the Board Nov 04 Grant / award · A RPRX +42,209 — — 1,350,029
Urist Marshall EVP, Research & Investments Nov 04 Grant / award · A RPRX +5,341 — — 5,341
Urist Marshall EVP, Research & Investments Oct 05 Open-market sale · S RPRX −4,126 $57.10 −$236K 0
Bassler Bonnie L Director Sep 30 Grant / award · A RPRX +642 $58.41 +$37.5K 79,823
Urist Marshall EVP, Research & Investments Sep 28 Open-market sale · S RPRX −4,126 $57.88 −$239K 4,126
Hite Christopher EVP & Chairman, Partnering Sep 22 Open-market sale · S RPRX −3,927 $58.93 −$231K 270,401
Hite Christopher EVP & Chairman, Partnering Sep 22 Open-market sale · S RPRX −96,073 $58.51 −$5.62M 274,328
Hite Christopher EVP & Chairman, Partnering Aug 19 Gift · G RPRX −16,800 — — 23,200
Hite Christopher EVP & Chairman, Partnering Aug 18 Open-market sale · S RPRX −100,000 $59.97 −$6M 370,401
Coyne Terrance P. EVP & CFO Aug 13 Open-market sale · S RPRX −1,772 $59.14 −$105K 0
Coyne Terrance P. EVP & CFO Aug 13 Open-market sale · S RPRX −9,230 $58.59 −$541K 1,772
Legorreta Pablo G. CEO, Chairman of the Board Aug 05 Grant / award · A RPRX +65,216 — — 1,307,820
Hite Christopher EVP & Chairman, Partnering Aug 05 Grant / award · A RPRX +11,002 — — 470,401
Coyne Terrance P. EVP & CFO Aug 05 Grant / award · A RPRX +11,002 — — 11,002
Urist Marshall EVP, Research & Investments Aug 05 Grant / award · A RPRX +8,252 — — 8,252

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support